Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin F Bachmann

Showing results (71-80 of 250) with videos related to

Pageof 25
Sort By:
Seminars in Immunology|September 10, 2017
Major findings and recent advances in virus-like particle (VLP)-based vaccinesMona O Mohsen, Lisha Zha, Gustavo Cabral-Miranda, et al.
Nature Medicine|March 8, 2006
Reply to 'Blood pressure vaccine shot down by safety concerns'Martin F Bachmann, Jürg Nussberger, Alain C Tissot, et al.
Expert Review of Vaccines|May 19, 2025
Virus-like particles: a versatile and effective vaccine platformMartin F Bachmann, Pierre van Damme, Florian Lienert, et al.
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology|August 29, 2019
Virus-like particles for vaccination against cancerMona O Mohsen, Daniel E Speiser, Alexander Knuth, et al.
The Journal of Allergy and Clinical Immunology|October 28, 2017
A novel recycling mechanism of native IgE-antigen complexes in human B cells facilitates transfer of antigen to dendritic cells for antigen presentationPaul Engeroff, Marc Fellmann, Daniel Yerly, et al.
Vaccines|June 7, 2019
Type of RNA Packed in VLPs Impacts IgG Class Switching-Implications for an Influenza Vaccine DesignAriane C Gomes, E S Roesti, Aadil El-Turabi, et al.
Journal for Immunotherapy of Cancer|March 23, 2026
γδ T cells at the interface of innate and adaptive immunity in cancerArnau Solé Casaramona, Martin F Bachmann, Eva Sevick-Muraca, et al.
Trends in Molecular Medicine|April 12, 2020
Vaccination against Allergy: A Paradigm Shift?Martin F Bachmann, Mona O Mohsen, Matthias F Kramer, et al.
Frontiers in Immunology|August 27, 2019
Virus-Specific Secondary Plasma Cells Produce Elevated Levels of High-Avidity Antibodies but Are Functionally Short LivedCaroline C Krueger, Franziska Thoms, Elsbeth Keller, et al.
European Journal of Immunology|February 10, 2004
Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the keyMartin F Bachmann, Lukas Hunziker, Rolf M Zinkernagel, et al.
Pageof 25

Showing results (71-80 of 250) with videos related to

Sort By:
Pageof 25
Seminars in Immunology|September 10, 2017
Major findings and recent advances in virus-like particle (VLP)-based vaccinesMona O Mohsen, Lisha Zha, Gustavo Cabral-Miranda, et al.
Nature Medicine|March 8, 2006
Reply to 'Blood pressure vaccine shot down by safety concerns'Martin F Bachmann, Jürg Nussberger, Alain C Tissot, et al.
Expert Review of Vaccines|May 19, 2025
Virus-like particles: a versatile and effective vaccine platformMartin F Bachmann, Pierre van Damme, Florian Lienert, et al.
Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology|August 29, 2019
Virus-like particles for vaccination against cancerMona O Mohsen, Daniel E Speiser, Alexander Knuth, et al.
The Journal of Allergy and Clinical Immunology|October 28, 2017
A novel recycling mechanism of native IgE-antigen complexes in human B cells facilitates transfer of antigen to dendritic cells for antigen presentationPaul Engeroff, Marc Fellmann, Daniel Yerly, et al.
Vaccines|June 7, 2019
Type of RNA Packed in VLPs Impacts IgG Class Switching-Implications for an Influenza Vaccine DesignAriane C Gomes, E S Roesti, Aadil El-Turabi, et al.
Journal for Immunotherapy of Cancer|March 23, 2026
γδ T cells at the interface of innate and adaptive immunity in cancerArnau Solé Casaramona, Martin F Bachmann, Eva Sevick-Muraca, et al.
Trends in Molecular Medicine|April 12, 2020
Vaccination against Allergy: A Paradigm Shift?Martin F Bachmann, Mona O Mohsen, Matthias F Kramer, et al.
Frontiers in Immunology|August 27, 2019
Virus-Specific Secondary Plasma Cells Produce Elevated Levels of High-Avidity Antibodies but Are Functionally Short LivedCaroline C Krueger, Franziska Thoms, Elsbeth Keller, et al.
European Journal of Immunology|February 10, 2004
Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the keyMartin F Bachmann, Lukas Hunziker, Rolf M Zinkernagel, et al.
Pageof 25